文献速递老年精神心境障碍

[18F]FDG PET 对抑郁性认知障碍鉴别诊断的增量价值

[18F]Fluorodeoxyglucose position emission tomography for differential diagnosis of depressive cognitive impairment: incremental value compared with clinical diagnosis.
PubMed 文献 · Br J Psychiatry · 2025-05-08

以中位随访6.6个月后的多学科生物标志物支持共识诊断为参考,PET披露后一级诊断改变23%,准确率从72%升至92%;二级诊断改变30%,准确率从64%升至85%。

要点

  • PET披露后一级诊断改变23%,准确率由72%升至92%。
  • PET披露后二级诊断改变30%,准确率由64%升至85%。
  • PET对排除神经退行性疾病尤其有价值。

核心结论

  • [18F]FDG PET在抑郁性认知障碍中提供超越临床诊断的显著增量诊断价值。
  • 应考虑将[18F]FDG PET纳入精神障碍伴认知障碍患者的诊断评估。

研究设计与样本

  • 基线临床诊断在[18F]FDG PET披露前后独立确立,一级分为神经退行性或非神经退行性疾病。
  • 神经退行性病例进一步分配至阿尔茨海默病、路易体病、额颞叶变性、其他神经退行性病亚组(二级)。
  • 以[18F]FDG PET后中位随访6.6个月的多学科生物标志物支持共识诊断为参考标准。

主要发现

  • PET披露后一级临床诊断改变23%(95%CI 16-33%),准确率从72%(95%CI 62-81%)提升至92%(95%CI 84-96%)(P < 0.001)。
  • PET对排除神经退行性疾病尤其有价值。
  • 二级临床诊断改变30%(95%CI 21-40%),准确率从64%(95%CI 54-74%)提升至85%(95%CI 76-91%)(P < 0.001)。
  • 二级错误诊断中相当一部分为阿尔茨海默病被误诊为路易体病。

关键数值与推荐

  • 一级诊断准确率:PET前72%(95%CI 62-81%),PET后92%(95%CI 84-96%),P < 0.001。
  • 二级诊断准确率:PET前64%(95%CI 54-74%),PET后85%(95%CI 76-91%),P < 0.001。
  • 一级诊断改变率23%(95%CI 16-33%),二级诊断改变率30%(95%CI 21-40%)。

临床怎么用

  • 对抑郁伴认知障碍患者,在临床诊断基础上考虑加做[18F]FDG PET以辅助鉴别神经退行性疾病。
  • PET尤其有助于排除神经退行性疾病,并可减少阿尔茨海默病误诊为路易体病的情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Assessment of regional glucose metabolism by [18F]fluorodeoxyglucose position emission tomography ([18F]FDG PET) serves as a biomarker for differential diagnosis of dementia. Conversely, depressive cognitive impairment shows no abnormalities on cerebral [18F]FDG PET. AIMS: This study validates the diagnostic value of [18F]FDG PET in addition to clinical diagnosis in a real-life gerontopsychiatric clinical population. METHOD: Ninety-eight consecutive patients with depression and cognitive impairment were included. Baseline clinical diagnoses were independently established before and after disclosure of [18F]FDG PET, and dichotomised into neurodegenerative or non-neurodegenerative diseases (level 1). Subsequently, neurodegenerative cases were allocated to diagnostic subgroups (Alzheimer's disease, Lewy body diseases, frontotemporal lobar degeneration, neurodegenerative other; level 2). An interdisciplinary, biomarker-supported consensus diagnosis after a median follow-up of 6.6 month after [18F]FDG PET served as reference. Changes of clinical diagnoses and diagnostic accuracy were assessed. RESULTS: After disclosure of [18F]FDG PET, level-1 clinical diagnoses changed in 23% (95% CI 16-33%) of cases, improving the diagnostic accuracy from 72% (95% CI 62-81%) to 92% (95% CI 84-96%) (P < 0.001). [18F]FDG PET was of particular value for exclusion of neurodegenerative disease. Concerning level-2 decisions, the clinical diagnoses changed in 30% (95% CI 21-40%) of cases, increasing its accuracy from 64% (95% CI 54-74%) to 85% (95% CI 76-91%) (P < 0.001). A major fraction of incorrect level-2 diagnoses comprised Alzheimer's disease misdiagnosed as Lewy body diseases. CONCLUSIONS: [18F]FDG PET provides a significant incremental diagnostic value beyond the clinical diagnosis in depressive cognitive impairment. Thus, [18F]FDG PET should be considered in the diagnostic work-up of patients with mental disorders and cognitive impairment.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hellwig S, Frings L, Heibel M, et al. [18F]Fluorodeoxyglucose position emission tomography for differential diagnosis of depressive cognitive impairment: incremental value compared with clinical diagnosis. Br J Psychiatry. 2025. PMID: 40337859. doi:10.1192/bjp.2025.67

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。